Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Oct 30, 2023 2:51pm
128 Views
Post# 35707766

RE:Any opinions as to how well the offering is selling?

RE:Any opinions as to how well the offering is selling?This was structured in a way to happen so fast it couldn't flop. The deal was done nearly immediately after it was announced last Wednesday. There was no roadshow to sell it as if there had been, it likely would have not been successful.

The company has its money and its leadership has job security, so they are no longer as concerned about the share price. This was a small stock offering so Cantor is not making so much money that it can afford to support the stock price for very long. Legacy shareholders were abused massively in this deal and are understandably selling in anger. As a result, the share price is falling below $1.

I certainly understand the selling as what has happened with this deal and over the last five years  have been pretty awful. But if you run the numbers, the stock is too cheap to sell if you assume sales are going to be maintained. If TH-1902 gets promising results, you still have a lot of upside, just half of what it would have been previously. 

juniper88 wrote: Would we see the offer (the public portion) reflected in the daily volume?

And can we ascertain anything from the fact that THTX has been trading less than 95 cents/share during this time?

I have seen other companies do offerings and the share price was identical to the offering price. 

I guess I am hopeful that this will be a flop.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse